Search Results for "meetings"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for meetings. Results 91 to 100 of 170 total matches.

Eliglustat (Cerdelga) - An Oral Drug for Gaucher Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015  (Issue 1472)
to imiglucerase in the percentage of patients meeting the primary endpoint (85% vs 94%, respectively).4 ADVERSE ...
The FDA has approved eliglustat (Cerdelga – Genzyme), an oral glucosylceramide synthase inhibitor, for treatment of adults with type 1 Gaucher disease. Eliglustat is metabolized primarily by CYP2D6. Because patients who are CYP2D6 ultra-rapid metabolizers may not achieve therapeutic concentrations and a specific dosage cannot be recommended for indeterminate metabolizers, the FDA has approved the drug only for patients who are extensive, intermediate, or poor metabolizers of CYP2D6.
Med Lett Drugs Ther. 2015 Jul 6;57(1472):e100-1 |  Show IntroductionHide Introduction

FDA Authorizes Johnson & Johnson COVID-19 Vaccine

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021  (Issue 1620)
for the prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee meeting. February 26 ...
On February 27, 2021, the FDA issued an Emergency Use Authorization (EUA) for the Johnson & Johnson adenovirus-based vaccine for prevention of COVID-19 in persons ≥18 years old. It is the third COVID-19 vaccine to become available in the US and the first to require only a single dose. Two-dose mRNA-based vaccines manufactured by Pfizer-BioNTech and Moderna received EUAs in December 2020.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):41-2 |  Show IntroductionHide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
Meeting. February 4, 2022. Available at: https://bit.ly/3IxhPjZ. Accessed March 3, 2022. 3. SA Buchan ...
The CDC has issued new guidance allowing for an interval of up to 8 weeks between the first and second primary doses of an mRNA COVID-19 vaccine in certain patients 12-64 years old.1 Product labeling currently recommends a 3-week interval between the first two doses of the Pfizer/BioNTech mRNA vaccine (Comirnaty) and a 4-week interval between the first two doses of the Moderna mRNA vaccine (Spikevax). The new guidance is based on data suggesting that a longer interval can decrease the risk of myocarditis and may improve vaccine efficacy.
Med Lett Drugs Ther. 2022 Mar 21;64(1646):47-8 |  Show IntroductionHide Introduction

H. Influenzae Vaccine For Infants

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 1991  (Issue 836)
Santosham et al, FDA Vaccines and Related Biological Products Advisory Committee, public meeting, Aug 20 ...
The US Food and Drug Administration (FDA) recently approved HibTITER (Lederle-Praxis) and PedvaxHIB (Merck), two new Haemophilus influenzae type b conjugate vaccines, for use in infants as part of their primary immunization schedule.
Med Lett Drugs Ther. 1991 Jan 25;33(836):5-7 |  Show IntroductionHide Introduction

Ziprasidone (Geodon) For Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001  (Issue 1106)
mg b.i.d. (G Simpson et al, abstract NR252 and poster presented at the Annual Meeting ...
Ziprasidone (Geodon - Pfizer), a benzisothiazolyl piperazine, has been approved by the FDA for oral treatment of schizophrenia. An intramuscular formulation will probably be available in the near future.
Med Lett Drugs Ther. 2001 Jun 11;43(1106):51-2 |  Show IntroductionHide Introduction

Problems With Dietary Supplements

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2002  (Issue 1140)
dietary supplements that meet the same Good Manufacturing Practices (GMPs) used to prepare prescription ...
Millions of people now take herbal products and other "dietary supplements." The Physicians' Desk Reference has published a PDR for Herbal Medicines listing their ingredients and indications, and the Drug Topics Red Book lists their prices.
Med Lett Drugs Ther. 2002 Sep 30;44(1140):84-6 |  Show IntroductionHide Introduction

Lowering Plasma Homocysteine

   
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003  (Issue 1168)
Coronary Intervention Trial [FACIT], Am Coll Cardiol 52 nd Annual Meeting, 2003). A 2-year open-label ...
High plasma homocysteine concentrations, like high cholesterol, have been associated with an increased risk of cardiovascular disease and death (O Nygσrd et al, N Engl J Med 1997; 337:230; RS Vasan et al, JAMA 2003; 289:1251). In one meta-analysis, 25% lower plasma homocysteine concentrations were associated with 11% less coronary heart disease and 19% less stroke (Homocysteine Studies Collaboration, JAMA 2002; 288:2015). Should we be trying to lower serum homocysteine concentrations in our patients?
Med Lett Drugs Ther. 2003 Oct 27;45(1168):85-6 |  Show IntroductionHide Introduction

Vilazodone (Viibryd) - A New Antidepressant

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2011  (Issue 1368)
meeting of the American Psychiatric Association, New Orleans, LA, May 2010. 7. CD Chambers et al ...
Vilazodone (Viibryd – Forest), a selective serotonin reuptake inhibitor (SSRI) and partial 5-HT1A receptor agonist, has been approved by the FDA for treatment of depression. It has been claimed to have no sexual side effects and not to cause weight gain.
Med Lett Drugs Ther. 2011 Jul 11;53(1368):53-4 |  Show IntroductionHide Introduction

Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016  (Issue 1492)
study. Presented at the 73rd Annual Meeting of the American Academy of Dermatology, San Francisco ...
The FDA has approved Enstilar (Leo), an aerosol foam formulation of the synthetic vitamin D3 analog calcipotriene and the high-potency corticosteroid betamethasone dipropionate, for topical treatment of plaque psoriasis in adults. Topical ointment and suspension formulations of the same combination have been available for many years.
Med Lett Drugs Ther. 2016 Apr 11;58(1492):48-9 |  Show IntroductionHide Introduction

BioThrax and Anthrasil for Anthrax

   
The Medical Letter on Drugs and Therapeutics • May 09, 2016  (Issue 1494)
Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg ...
The FDA has approved anthrax vaccine adsorbed (AVA; BioThrax – Emergent BioSolutions) for prevention of anthrax disease in adults following exposure to Bacillus anthracis and intravenous anthrax immune globulin (Anthrasil – Emergent BioSolutions) for treatment of inhalation anthrax in adults and children. AVA has been available since 1970 for prevention of anthrax disease in persons at high risk of exposure.
Med Lett Drugs Ther. 2016 May 9;58(1494):62 |  Show IntroductionHide Introduction